Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and Treatment

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract / Description of output

The immense costs in both financial terms and pre-clinical research effort that occur in the development of anti-cancer drugs are unfortunately not matched by a substantial increase in improved clinical therapies due to the high rate of failure during clinical trials. This may be due to issues with toxicity, or lack of clinical ef-fectiveness when the drug is evaluated in patients. Currently, much cancer re-search is driven by the need to develop therapies that can exploit cancer cell ad-aptations to conditions in the tumor microenvironment such as acidosis and hy-poxia, the requirement for more-specific, targeted treatments, or the exploitation of ‘precision medicine’ that can target known genomic changes in patient DNA. The high attrition rate for novel anti-cancer therapies suggests that the pre-clinical methods used in screening anti-cancer drugs need improvement. This chapter considers the advantages and disadvantages of 3D organotypic models in both cancer research and cancer drug screening, particularly in the areas of targeted drugs and the exploitation of genomic changes that can be used for therapeutic advantage in precision medicine
Original languageEnglish
Title of host publication Current Topics in Microbiology and Immunology
EditorsFabio Bagnoli, Rino Rappuoli
Publication statusE-pub ahead of print - 12 Mar 2019

Publication series

NameCurrent Topics in Microbiology and Immunology


Dive into the research topics of 'Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and Treatment'. Together they form a unique fingerprint.

Cite this